Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis
Background and Aim. The effect of cannabis use on chronic liver disease (CLD) from Hepatitis C Virus (HCV) infection, the most common cause of CLD, has been controversial. Here, we investigated the impact of cannabis use on the prevalence of CLD among HCV infected individuals. Methods. We analyzed h...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2018/9430953 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850171440036315136 |
|---|---|
| author | Adeyinka Charles Adejumo Oluwole Muyiwa Adegbala Kelechi Lauretta Adejumo Terence Ndonyi Bukong |
| author_facet | Adeyinka Charles Adejumo Oluwole Muyiwa Adegbala Kelechi Lauretta Adejumo Terence Ndonyi Bukong |
| author_sort | Adeyinka Charles Adejumo |
| collection | DOAJ |
| description | Background and Aim. The effect of cannabis use on chronic liver disease (CLD) from Hepatitis C Virus (HCV) infection, the most common cause of CLD, has been controversial. Here, we investigated the impact of cannabis use on the prevalence of CLD among HCV infected individuals. Methods. We analyzed hospital discharge records of adults (age ≥ 18 years) with a positive HCV diagnosis. We evaluated records from 2007 to 2014 of the Nationwide Inpatient Sample (NIS). We excluded records with other causes of chronic liver diseases (alcohol, hemochromatosis, NAFLD, PBC, HBV, etc.). Of the 188,333 records, we matched cannabis users to nonusers on 1:1 ratio (4,728:4,728), using a propensity-based matching system, with a stringent algorithm. We then used conditional regression models with generalized estimating equations to measure the adjusted prevalence rate ratio (aPRR) for having liver cirrhosis (and its complications), carcinoma, mortality, discharge disposition, and the adjusted mean ratio (aMR) of total hospital cost and length of stay (LOS) [SAS 9.4]. Results. Our study revealed that cannabis users (CUs) had decreased prevalence of liver cirrhosis (aPRR: 0.81[0.72-0.91]), unfavorable discharge disposition (0.87[0.78-0.96]), and lower total health care cost ($39,642[36,220-43,387] versus $45,566[$42,244-$49,150]), compared to noncannabis users (NCUs). However, there was no difference among CUs and NCUs on the incidence of liver carcinoma (0.79[0.55-1.13]), in-hospital mortality (0.84[0.60-1.17]), and LOS (5.58[5.10-6.09] versus 5.66[5.25-6.01]). Among CUs, dependent cannabis use was associated with lower prevalence of liver cirrhosis, compared to nondependent use (0.62[0.41-0.93]). Conclusions. Our findings suggest that cannabis use is associated with decreased incidence of liver cirrhosis, but no change in mortality nor LOS among HCV patients. These novel observations warrant further molecular mechanistic studies. |
| format | Article |
| id | doaj-art-9d63f202f8024763836c77f1619da8f2 |
| institution | OA Journals |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-9d63f202f8024763836c77f1619da8f22025-08-20T02:20:16ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972018-01-01201810.1155/2018/94309539430953Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume CannabisAdeyinka Charles Adejumo0Oluwole Muyiwa Adegbala1Kelechi Lauretta Adejumo2Terence Ndonyi Bukong3Department of Medicine, North Shore Medical Center, Salem, MA, USADepartment of Medicine, Englewood Hospital and Medical Center, Englewood, NJ, USASchool of Public Health, University of Massachusetts Lowell, Lowell, MA, USADepartment of Medicine, University of Massachusetts Medical School, Worcester MA, USABackground and Aim. The effect of cannabis use on chronic liver disease (CLD) from Hepatitis C Virus (HCV) infection, the most common cause of CLD, has been controversial. Here, we investigated the impact of cannabis use on the prevalence of CLD among HCV infected individuals. Methods. We analyzed hospital discharge records of adults (age ≥ 18 years) with a positive HCV diagnosis. We evaluated records from 2007 to 2014 of the Nationwide Inpatient Sample (NIS). We excluded records with other causes of chronic liver diseases (alcohol, hemochromatosis, NAFLD, PBC, HBV, etc.). Of the 188,333 records, we matched cannabis users to nonusers on 1:1 ratio (4,728:4,728), using a propensity-based matching system, with a stringent algorithm. We then used conditional regression models with generalized estimating equations to measure the adjusted prevalence rate ratio (aPRR) for having liver cirrhosis (and its complications), carcinoma, mortality, discharge disposition, and the adjusted mean ratio (aMR) of total hospital cost and length of stay (LOS) [SAS 9.4]. Results. Our study revealed that cannabis users (CUs) had decreased prevalence of liver cirrhosis (aPRR: 0.81[0.72-0.91]), unfavorable discharge disposition (0.87[0.78-0.96]), and lower total health care cost ($39,642[36,220-43,387] versus $45,566[$42,244-$49,150]), compared to noncannabis users (NCUs). However, there was no difference among CUs and NCUs on the incidence of liver carcinoma (0.79[0.55-1.13]), in-hospital mortality (0.84[0.60-1.17]), and LOS (5.58[5.10-6.09] versus 5.66[5.25-6.01]). Among CUs, dependent cannabis use was associated with lower prevalence of liver cirrhosis, compared to nondependent use (0.62[0.41-0.93]). Conclusions. Our findings suggest that cannabis use is associated with decreased incidence of liver cirrhosis, but no change in mortality nor LOS among HCV patients. These novel observations warrant further molecular mechanistic studies.http://dx.doi.org/10.1155/2018/9430953 |
| spellingShingle | Adeyinka Charles Adejumo Oluwole Muyiwa Adegbala Kelechi Lauretta Adejumo Terence Ndonyi Bukong Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis Canadian Journal of Gastroenterology and Hepatology |
| title | Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis |
| title_full | Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis |
| title_fullStr | Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis |
| title_full_unstemmed | Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis |
| title_short | Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis |
| title_sort | reduced incidence and better liver disease outcomes among chronic hcv infected patients who consume cannabis |
| url | http://dx.doi.org/10.1155/2018/9430953 |
| work_keys_str_mv | AT adeyinkacharlesadejumo reducedincidenceandbetterliverdiseaseoutcomesamongchronichcvinfectedpatientswhoconsumecannabis AT oluwolemuyiwaadegbala reducedincidenceandbetterliverdiseaseoutcomesamongchronichcvinfectedpatientswhoconsumecannabis AT kelechilaurettaadejumo reducedincidenceandbetterliverdiseaseoutcomesamongchronichcvinfectedpatientswhoconsumecannabis AT terencendonyibukong reducedincidenceandbetterliverdiseaseoutcomesamongchronichcvinfectedpatientswhoconsumecannabis |